- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03044990
Prognosis of Patients With Acute Coronary Syndrome Complicated With Renal Insufficiency(PACS-RI) (PACS-RI)
Study on the Prognosis of Patients With Acute Coronary Syndrome Complicated With Renal Insufficiency: a Prospective, Multicenter, Observational Study
Several epidemiologic studies reported that patients with renal insufficiency might have increased cardiovascular disease-related mortality rates after Percutaneous coronary intervention (PCI) . The increased risk in this population may be related to the less use of standard guideline-based treatment and the resulting inability to perform PCI effectively. Recently, with the technology improvement and the progress in clinical trials, Chinese guidelines have made new recommendations about the patients with acute coronary syndrome(ACS) in different states of renal function. However, scant epidemiologic information exists on the prognosis of those patients, especially in Henan. And there is still some uncertainty whether those patients are using the latest guideline recommended treatment.
This multicenter, prospective, observational study is aimed to evaluate the long prognosis in patients with acute coronary syndrome complicated with renal insufficiency, and to analysis its related factors that influence the outcomes.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
- Henan institute of cardiology epidemiology is responsible for design, data quality control and statistical analysis.
- Data were collected using a uniformed Case Report Form(CRF) by trained staff at each hospital.
- Sample size estimation: Based on retrospective observational cohort of ACS patients, 1-year mortality in normal renal function and renal disfunction were 2.8% and 7.9%, respectively. To achieve a precision of 15% with an α of 0.05, the loss ratio of following-up is 10%.The investigators would need a sample of 2000.
- Statistical analysis plan: the investigators will report summary statistics for patient characteristics, renal function status, comorbidities, treatment strategies and outcomes. the investigators will also undertake the following prespecified subgroup analyses: age, sex, STE-ACS or NSTE-ACS, history of diabetes, history of hypertension, smoking and Syntax score.
- Quality assurance plan 1)Diagnosis of ACS is according to the third universal definition.2)Before registry, a training program on study objectives, data collection, and ACS management is given to the primary investigator and related staff at each participating center.3)Henan institute of cardiology epidemiology will regularly monitored at least 10% of CRFs for accuracy against medical records. If the CRFs are not completed with 98% accuracy, all CRFs are considered unqualified and this staff will be retrained.4)Before entering into the computer, data is queried for invalid and illogical values by research staff in Henan institute of cardiology epidemiology. Participating centres who has the high error rate of data, and no change in 6 months shall be deemed abandoned automatically; participating centres who has the high quality of data will be issued a certificate to reward.5)Investigator meeting will be annually held to conclude the progress, solve existing problems and strengthen program training.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Henan
-
Zhengzhou, Henan, Chine, 450000
- Henan Province People's Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Age≥18 years.
- Patients with clinical evidence of acute coronary syndrome, including ST segment elevation myocardial infarction (STEMI), non ST segment elevation myocardial infarction (NSTEMI) and unstable angina.
- Informed consent signed by patients or legal guardians.
Exclusion Criteria:
- Non-atherosclerotic coronary heart disease
- Organ failure other than heart failure and kidney failure
- Considered not fit for the study due to other reasons, including but not restricted to : a. Severe infection; b. cachexia;c.maintenance hemodialysis.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Major adverse cardiovascular and cerebrovascular events
Délai: 1 year
|
including all-caused death, nonfatal- myocardial infarction,and stroke
|
1 year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Major adverse cardiovascular and cerebrovascular events
Délai: At discharge(an average of 10 days),6 month
|
including all-caused death, nonfatal- myocardial infarction,and stroke
|
At discharge(an average of 10 days),6 month
|
|
Coronary revascularization
Délai: 6 month,1 year
|
6 month,1 year
|
|
|
Re-hospitalized
Délai: 6 month,1 year
|
6 month,1 year
|
|
|
Renal-Replaced therapy
Délai: At discharge(an average of 10 days),6 month,1 year
|
At discharge(an average of 10 days),6 month,1 year
|
|
|
Bleeding according to GUSTO bleeding grade(excluding hemorrhage stroke)
Délai: At discharge(an average of 10 days),6 month,1 year
|
At discharge(an average of 10 days),6 month,1 year
|
|
|
Cardiogenic shock
Délai: At discharge(an average of 10 days)
|
At discharge(an average of 10 days)
|
|
|
New arrhythmia
Délai: At discharge(an average of 10 days)
|
At discharge(an average of 10 days)
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Chuanyu Gao, MD, Henan Institute of Cardiovascular Epidemiology
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- HenanICE201603
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .